Acyclovir: An Updated Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy

Drugs

Volumn 37, Issue 3, 1989, Pages 233-309

  O’Brien, John J ^a   Campoli Richards, Deborah M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ALPHA INTERFERON; FIACITABINE; GANCICLOVIR; IDOXURIDINE; THYMIDINE KINASE; TRIFLURIDINE; VIDARABINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD LEVEL; CELL CULTURE; CLINICAL ARTICLE; CROSS RESISTANCE; CYTOMEGALOVIRUS; DRUG ABSORPTION; DRUG RESISTANCE; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN EXPERIMENT; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; TREMOR; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ACYCLOVIR; ANIMAL; HUMAN; VIRUS DISEASES;

EID: 0024599205     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198937030-00002     Document Type: Article

References (385)

1. Diffuse herpes simplex virus colitis in a kidney transplant recipient successfully treated with acyclovir
2. Controlled clinical trial of acyclovir in chronic hepatitis B virus infection
3. Controlled trial of acyclovir in chronic HBsAg, HBeAg positive carriers. Abstract
4. Susceptibility of HSV strains from patients with genital herpes treated with various formulations of acyclovir
5. A randomised controlled study of intravenous acyclovir (Zovirax*) against placebo in adults with chickenpox
6. Prophylaxis: a strategy to minimise antiviral resistance
7. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukemia patients receiving remission induction chemotherapy: a randomised double blind, placebo controlled trial
8. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study
9. Acyclovir treatment in primary Epstein-Barr virus infection
10. Adverse reactions to acyclovir: topical, oral and intravenous
11. Acyclovir and neurologic manifestations
12. Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella zoster virus strains
13. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro
14. Acyclovir halts progression of herpes zoster in immunocompromised patients
15. Acyclovir in cytomegalovirus infection 3½ years after renal transplantation
16. Viral resistance in clinical practice: summary of five years experience with acyclovir
17. Clinical and laboratory experience with acyclovir-resistant herpes viruses
18. Viral resistance; clinical experience
19. Recurrences after first episodes of genital herpes in patients treated with topical acyclovir cream
20. Psychiatric side-effects with acyclovir
21. Lymphomatoid papulosis: remission following intravenously administered acyclovir
22. Hepatitis due to herpes simplex virus in a nonpregnant patient: treatment with acyclovir
23. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster
24. Acyclovir therapy for acute herpes zoster
25. Neurotransmitter reactivation of HSV-1 infection. Abstract
26. Acyclovir versus Trifluorthymidin in der Therapie der Stromalen Herpes-Keratitis
27. Herpes encephalitis during pregnancy: failure of acyclovir and adenine arabinoside to prevent neonatal herpes
28. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir
29. Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro
30. In vitro susceptibility of varicella zoster to acyclovir
31. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus
32. Long-term oral acyclovir treatment prevents recurrent genital herpes
33. Overview of acyclovir pharmacokinetic disposition in adults and children. Acyclovir Symposium
34. Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis
35. Acyclovir therapy for chickenpox in children with haematological malignancies
36. Herpes simplex acyclovir-resistant mutant in experimental keratouveitis
37. A case of herpes zoster associated encephalitis treated with acyclovir
38. Acyclovir, a new antiherpetic drug: early experience in man with systemically administered drug
39. The clinical pharmacology of acyclovir and its prodrugs
40. Infectious complications in heart-lung transplant recipients
41. Acyclovir disposition in critically ill patients with herpes virus infections on continuous peritoneal dialysis
42. Acyclovir and varicella pneumonia
43. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir
44. Acyclovir bei Mycosis fungoides und lymphomatoides Papulose
45. Disseminated herpes simplex infection in an immunocompromised pregnancy: treatment with intravenous acyclovir
46. A case of herpes zoster associated encephalitis with rapid response to acyclovir
47. Properties of herpes virus-specific thymidine kinase, DNA polymerase and DNase and their implication in the development of specific antiherpes agents
48. Unique spectrum of activity of 9-[1,3-dihydroxy-(2-propoxy)methyl] guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1
49. Acyclovir in the treatment of primary varicella pneumonia in adults. Abstract
50. Combined effects of acycloguanosine and humoral antibodies in experimental encephalitis due to herpesvirus hominis
51. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient
52. Clinical resistance to acyclovir of herpes simplex virus infections in immunocompromised patients
53. Discussion
54. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus: an interim report
55. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus
56. Replication of Epstein-Barr virus DNA in lymphoblastoid cells treated for extended periods with acyclovir
57. Varicella-zoster virus does not become more resistant to acyclovir during therapy
58. In vitro susceptibility of cytomegalo-virus isolates from immunocompromised patients to acyclovir and ganciclovir
59. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir
60. The spectrum of antiviral activities of acyclovir in vitro and in vivo
61. Viral sensitivity following the introduction of acyclovir. Antiviral Symposium
62. Acyclovir treatment of cutaneous herpes in guinea pigs and herpes encephalitis in mice
63. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir
64. Oral acyclovir in herpetic keratitis
65. A double-blind comparative trial of acyclovir and adenine arabinoside in combination with dilute betamethasone in the management of herpetic disciform keratitis
66. Acyclovir in complicated herpetic keratitis
67. Acyclovir (Zovirax) in herpetic disciform keratitis
68. Randomised double-blind trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex amoeboid corneal ulceration
69. Acyclovir in accelerated phase of Chediak-Higashi syndrome
70. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice
71. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical intravenous and oral therapy
72. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections
73. Intravenous acyclovir for the treatment of primary genital herpes
74. Trial of topical acyclovir in genital herpes simplex virus infections
75. Treatment of disseminated herpes simplex virus in pregnancy with parenteral acyclovir
76. Comparative activities of combinations of acyclovir, vidarabine or its 5′-monophosphate, and cloned human interferons against herpes simplex virus type 2 in human and mouse fibroblast cultures
77. Comparative activities of selected combinations of vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice
78. Enhanced efficacy of nucleoside analogs and recombinant alpha interferon in weanling mice lethally infected with herpes simplex virus type 2
79. Resistance of herpes simplex virus to antiviral agents: is it clinically important?
80. Varicella zoster virus is a cause of acute retinal necrosis syndrome
81. Cooperative effects between two acyclovir resistant loci in herpes simplex virus
82. Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids
83. Herpes simplex infections in atopic eczema
84. −) mutants of herpes simplex virus
85. In vitro susceptibility of varicella zoster to ϵ-5-(2-bromovinyl)-2′-deoxyuridine and related compounds
86. Antiviral activity of 5-(2-halogenovinyl)-2′-deoxyuridines
87. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus
88. Viral resistance in clinical practice
89. Combination therapy for dendritic keratitis with acyclovir and α-interferon
90. Effects of acyclovir therapy during simultaneous reactivation of latent HSV-1 in rabbits
91. Pharmacokinetics of acyclovir after intravenous and oral administration
92. Metabolic fate of radioactive acyclovir in humans. Acyclovir Symposium
93. Species differences in the disposition of acyclovir
94. Acyclovir kinetics after intravenous infusion
95. Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice
96. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects
97. Drugs five years later: acyclovir
98. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
99. La stomato-gingivite herpétique de l’enfant: essai controlé aciclovir versus placebo
100. Suppression of HSV-1 infection in trigeminal ganglion cells
101. Varicella pneumonia during pregnancy: treatment of two cases with acyclovir
102. Acyclovir and disseminated varicella zoster and encephalitis
103. Acyclovir
104. Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs
105. Prophylactic topical acyclovir for frequent herpes simplex infection with and without erythema multiforme
106. Acyclovir: an update of the clinical applications of this antiherpes agent
107. Topical acyclovir in the management of recurrent herpes labialis
108. Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy
109. Treatment of herpes labialis
110. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene
111. Oral acyclovir for herpes zoster
112. Failure of topical acyclovir in ointment to penetrate human skin
113. Topical recombinant interferon compared to acyclovir in the treatment of an experimental herpes simplex virus infection
114. Efficacy of topical treatment for herpes simplex virus infections: predictions from an index of drug characteristics in vitro
115. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses
116. Viral origin of hairy leukoplakia
117. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase
118. Nucleic and hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication
119. Wirksamkeitsvergleich von Aciclovir und Vidarabin bei oberflächlichen Herpeskeratitiden
120. Prophylaxis against herpes labialis with acyclovir cream: a placebo-controlled study
121. Acyclovir for immunocompromised patients with herpes zoster
122. The red eye
123. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir
124. Acyclovir prophylaxis for herpes simplex virus infection
125. Episodic twice-daily treatment for recurrent genital herpes. Antiviral Symposium
126. Oral acyclovir for episodic treatment of recurrent genital herpes
127. Erythema multiforme due to herpes simplex: treatment with oral acyclovir
128. Acyclovir (Zovirax®) ophthalmic ointment: a review of clinical tolerance
129. Reaction to oral acyclovir
130. Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir
131. Oral ‘hairy’ leukoplakia in male homosexuals: evidence of association with both papillomavirus and a herpes-group virus
132. Transplacental passage of acyclovir
133. Systemic acyclovir in pregnancy: a case report
134. Treatment of chronic HBeAg-positive hepatitis with acyclovir: a controlled trial
135. An open study of human lymphoblastoid interferon and oral acyclovir in chronic hepatitis B virus infection
136. Acyclovir treatment of herpes simplex encephalitis: experience in a district hospital
137. Transplacental passage of acyclovir
138. Acyclovir in herpes zoster oticus
139. Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study
140. Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures
141. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double-blind trial
142. Intracellular pools of thymidine reduce the antiviral action of acyclovir
143. Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells
144. Influence of cells and virus multiplicity on the inhibition of herpesvirus with acycloguanosine
145. Multiplicity dependence and sensitivity of herpes simplex virus isolates to antiviral compounds
146. Combined antiviral effects of acyclovir or bromovinyldeoxyuridine and human immunoglobulin in herpes simplex virus-infected mice
147. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections
148. Successful management of acute retinal necrosis with intravenous acyclovir
149. Aciclovir et trifluorothymidine dans la kérato-uvéite herpétique: une étude comparative en clinique humaine
150. Acyclovir for recurrent erythema multiforme caused by herpes simplex
151. Therapy of herpes zoster with oral acyclovir. Antiviral Symposium
152. Oral acyclovir in the management of dendritic herpetic corneal ulceration
153. Pharmacokinetics of oral acyclovir (Zovirax) in the eye
154. Acyclovir treatment in a case of facial paralysis caused by herpes zoster
155. Treatment of herpes simplex keratitis: comparison of acyclovir and vidarabine
156. Treatment of excema herpeticum with systemic acyclovir
157. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature
158. The disposition of 6-deoxyacyclovir, a xanthine oxidase-activated prodrug of acyclovir, in the isolated perfused rat liver
159. Rapid response to acyclovir in herpes zoster-associated encephalitis
160. High-dose intravenous acyclovir in the treatment of zoster: a double-blind, placebo-controlled trial
161. Acyclovir in endoscopically presumed viral esophagitis
162. Synergistic antiviral effects of acyclovir and vidarabine on herpes simplex infection in newborn mice
163. Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex type 1
164. Synergistic inhibitory effect of acyclovir and human native beta-interferon on the growth of herpes simplex virus type 2 in human embryo fibroblast cell cultures
165. Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir
166. Acyclovir treatment of experimental genital herpes simplex virus injections
167. Acyclovir treatment of disseminated herpes simplex virus type 2 infection in weanling mice: alteration of mortality and pathogenesis
168. Topical acyclovir in the treatment of recurrent herpes simplex virus infections
169. Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes
170. Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes
171. Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study
172. Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes
173. Failure of acyclovir cream in treatment of recurrent herpes labialis
174. Acyclovir and idoxuridine treatment of herpes simplex keratitis: a double-blind clinical study
175. Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice
176. Effect of discontinuous acyclovir treatment on in vitro reactivation of herpes simplex virus from latently infected trigeminal ganglia
177. Allopurinal as an inhibitor of the in vivo formulation of acyclovir from desciclovir
178. Reversible neurotoxicity to oral acyclovir in a patient with chronic lymphocytic leukemia
179. Acyclovir treatment of twelve unexplained infertile couples
180. Topical acyclovir ointment in the treatment of genital herpes simplex virus infections
181. Disseminated herpes simplex virus infection in pregnancy: successful treatment with acyclovir
182. Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig
183. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities
184. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir
185. Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type I
186. Effect of low dose acyclovir (5 mg/kg) on virus shedding, interferon and humoral immunity in herpes zoster
187. Clinical pharmacokinetics of acyclovir
188. Acyclovir and suppression of frequently recurring herpetic whitlow
189. Acyclovir kinetics in end-stage renal disease
190. Unexpected accumulation of acyclovir in breast milk with estimation of infant exposure
191. Acyclovir and pregnancy
192. Oral acyclovir for the prevention of herpes-associated erythema multiforme
193. Inhibition of human herpesviruses by combinations of acyclovir and human leukocyte interferon
194. Topical acyclovir treatment of herpes zoster in immunocompromised patients
195. Human gastrointestinal absorption of acyclovir from tablet, duodenal infusion and sipped solution
196. Nausea and vomiting possibly associated with intravenous acyclovir
197. Identification of an Epstein-Barr virus-coded thymidine kinase
198. Effects of 2,2′-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice
199. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro
200. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo
201. Sensitivity of labial and genital isolates of herpes simplex virus to topical and oral acyclovir
202. Plaque autoradiography assay for the detection and quantification of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates
203. Effect of topical acyclovir therapy on experimental herpes simplex keratouveitis
204. Herpes zoster ocular infection
205. A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis
206. A review of acyclovir treatment of ocular herpes and skin infections
207. Intravenous acyclovir in acute herpes zoster infection
208. Identification of small DNA fragments synthesized in herpes simplex-infected cells in the presence of acyclovir
209. Oral acyclovir in herpes zoster
210. Oral acyclovir in herpes zoster
211. Oral acyclovir in acute herpes zoster
212. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir
213. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients
214. Response of immunocompromised patients with acute herpes zoster to intravenous acyclovir
215. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection
216. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Antiviral Symposium
217. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection
218. Acyclovir in human breast milk
219. Treatment of herpesvirus infections in the immunocompromised host
220. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
221. Multicenter collaborative trial of intravenous acyclovir for treatment of mucotaneous herpes simplex virus infection in the immunocompromised
222. Acyclovir treatment of varicella-zoster virus infection in the immunocompromised host
223. Ganglionic permissivity to HSV-1 replication and acyclovir-induced latency: an in vitro model
224. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes
225. Treatment of first-attack genital herpes: acyclovir versus inosine pranobex
226. Genital herpes: the disease and its treatment including intravenous acyclovir
227. Prophylactic oral acyclovir in recurrent genital herpes
228. Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV
229. Oral acyclovir prevents herpes simplex virus-associated erythema multiforme
230. Effects of acyclovir on herpes virus infection and susceptibility of isolated virus to acyclovir
231. Prophylactic and therapeutic treatment with acyclovir of genital herpes in the guinea pig
232. Treatment of herpes zoster encephalitis with acyclovir. Abstract
233. Genital herpes
234. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
235. Treatment of eczema herpeticum with oral acyclovir. Antiviral Symposium
236. Acyclovir administered perorally in immunocompromised children with varicella-zoster infections
237. Recurrent genital herpes and suppressive oral acyclovir therapy: relation between clinical outcome and in-vitro drug sensitivity
238. In vitro sensitivity to acyclovir of herpesvirus shed in patients receiving either chronic suppressive or episodic oral therapy. Abstract
239. Extended acyclovir therapy for herpes genitalis: changes in virus sensitivity and strain variation
240. Acyclovir prevents dissemination of varicella in immunocompromised children
241. Recurrent varicella-zoster infection after acyclovir therapy in immunocompromised patients
242. Antiviral chemotherapy of oral and genital herpes simplex infections
243. Experimental neonatal herpes simplex virus type 2 (HSV-2) infection: comparison of treatment with adenine arabinoside (ara-A), ara-A-5′-monophosphate (ara-AMP) and acyclovir (ACV)
244. Prophylactic or anticipatory antiviral therapy for new-borns exposed to herpes simplex infection
245. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses
246. Acyclovir and Epstein-Barr virus infection
247. Antiviral activity of Win 412583, a pyrazole compound against herpes simplex virus in mouse genital infection and in guinea pig skin infection
248. Disseminated herpes simplex infection complicating Darier’s disease: successful treatment with oral acyclovir
249. Effect of combined acyclovir and vidarabine on infection with herpes simplex virus in vitro and in vivo
250. Effect of acyclovir, bromovinyldeoxyuridine, vidarabine and L-lysine on latent ganglionic herpes simplex virus in vitro
251. Acyclovir in oral and ganglionic herpes simplex virus infections
252. Acyclovir topical therapy of cutaneous herpes simplex virus infection in guinea pigs
253. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase
254. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates
255. Acyclovir antimetabolite therapy of experimental herpes simplex keratitis
256. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Antiviral Symposium
257. Oral and intravenous acyclovir are equally effective in herpes zoster
258. Acyclovir in herpes zoster
259. Prophylactic oral acyclovir after renal transplantation
260. Vitrectomy and intravitreal antiviral drug therapy in acute retinal necrosis syndrome
261. In vitro and in vivo responses of cytomegalovirus to acyclovir
262. Human aqueous penetration of topically applied acyclovir ophthalmic ointment, 3%
263. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds
264. Resistance of peripheral autonomic neurons to in vivo productive infection by herpes simplex virus mutants deficient in thymidine kinase
265. Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study
266. Effect of antiviral agents on replication of herpes simplex virus type 1 in brain cultures
267. Oral acyclovir for genital herpes: cautious optimism
268. Correspondence
269. Oral acyclovir and herpes labialis: a randomised, double-blind, placebo-controlled study
270. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-β-D-arabino-furanosyluracil: comparison with bromovinyldeoxyuridine and acyclovir
271. Efficacy of 5-vinyl-1-β-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet
272. Treatment of recurrent genital herpes simplex infections with oral acyclovir
273. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
274. In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin
275. Acyclovir: a review of its pharmacodynamic properties and therapeutic efficacy
276. Treatment with acyclovir of genital herpes simplex virus infection complicated by eczema herpeticum
277. Cutaneous adverse reactions to acyclovir: case reports
278. Oral acyclovir for treatment of first-episode herpes simplex virus proctatitis
279. Herpes simplex encephalitis in a patient with lymphoma: relapse following acyclovir therapy
280. Overdose with acyclovir in a CAPD patient
281. Treatment of recurrent genital herpes simplex infections with oral acyclovir
282. The role of acyclovir in the management of genital herpes simplex
283. Suppression of recurrent genital herpes with oral acyclovir
284. Double-blind placebo-controlled trial of oral acyclovir in recurrent genital herpes
285. Acyclovir in the treatment of herpetic stromal disease
286. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia
287. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized double-blind controlled trial in bone-marrow-transplant recipients
288. Acyclovir-induced renal failure
289. Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B
290. Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon
291. Abatement of Sézary syndrome lesions following treatment with acyclovir
292. Drug combination for treatment of mice infected with acyclovir-resistant herpes simplex virus
293. Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and ápplication of the median effect method of analysis
294. Characterisation of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency
295. Activities of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2
296. Different in vitro effects of dual combinations of anti-herpes simplex virus (HSV) compounds
297. Therapeutic activities of 1-(2-fluoro-2-deoxy-gb-D-arabinosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus
298. Effect of combination of acyclovir, and vidarabine or its 5′-monophosphate on herpes simplex viruses in cell culture and in mice
299. Acyclovir treatment of disseminated varicella in childhood malignant neoplasms
300. The intraocular penetration of acyclovir after subconjunctival administration
301. Oral acyclovir in the management of herpes simplex ocular infections
302. Acyclovir and the treatment of herpetic whitlow
303. Prevention of herpes simplex virus infections in renal allograft recipients by low-dose oral acyclovir
304. Amino(hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir
305. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis
306. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis
307. Failure of acyclovir cream in treatment of recurrent herpes labialis
308. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients
309. Treatment of varicellazoster virus infection in severely immunocompromised patients: a randomised comparison of acyclovir and vidarabine
310. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised bone marrow transplant recipients
311. Intravenous lymphoblastoid interferon and acyclovir for treatment of cytomegaloviral pneumonia
312. Comparative efficacy of antiherpes drugs against various strains of varicella zoster virus
313. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child
314. Acyclovir therapy of neonatal herpes simplex virus type 2 infections of rabbits
315. Major depression with psychotic features associated with acyclovir therapy
316. Acyclovir versus vidarabine in herpes simplex encephalitis: randomised multicentre study in consecutive Swedish patients
317. Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl) guanine, acyclovir, and two 2′-fluoropyrimidine nucleosides
318. Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus
319. The use of in-vitro sensitivity testing to predict clinical response of recurrent herpes simplex to suppressive oral acyclovir
320. Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion
321. Inhibition of human cytomegalovirus by combined acyclovir and vidarabine
322. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus
323. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis: antiviral effect without clinical benefit
324. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir
325. Comparison of topically applied 5-ethyl-2′-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs
326. Combined action of interferon and acyclovir on herpes simplex type 1 and 2 in vero cells
327. Effectiveness of oral acyclovir prophylaxis in renal transplant recipients
328. Acyclovir suppression of frequently recurring genital herpes
329. Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients
330. Double-blind comparison of weekend and daily regimens of acyclovir for suppression of recurrent genital herpes
331. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients
332. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir
333. Pharmacokinetics of acyclovir suspension in infants and children
334. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′-dideoxythymidine (Azidothymidine or Zidovudine) and acyclovir: a pilot study
335. Sensitivity of HSV strains isolated before and after treatment with acyclovir
336. Vesicular eruption: a local complication of concentrated acyclovir infusions
337. A competitive enzyme-linked immunosorbent assay to quantitate acyclovir and BW B759U in human plasma and urine
338. Acyclovir therapy for eczema herpeticum in infants
339. Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion
340. Acute and latent infection by thymidine kinase mutants of herpes simplex virus type 2
341. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus
342. Recurrent genital herpes suppressed by oral acyclovir: a multi-centre double blind trial
343. Topical acyclovir in the treatment of initial genital herpes
344. Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection
345. Psychiatric side-effects of acyclovir in patients with chronic renal failure
346. Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection
347. Update on acyclovir: oral therapy for herpesvirus infections
348. Treatment of herpetic whitlow in pregnancy with acyclovir
349. In vitro activity of acyclovir and related compounds against cytomegalovirus infections
350. Unilateral acute uveitis with periarteritis and detachment
351. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study
352. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis
353. Relapse of herpes simplex encephalitis after conventional acyclovir therapy
354. Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labelled monoclonal antibodies
355. Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections
356. Intravenous acyclovir and neurologic effects
357. Comparative trial of acyclovir and vidarabine in disseminated varicella-zoster virus infections in immunocompromised patients
358. Chronic herpetic infection in an immunocompromised patient: report of a case
359. Treatment of cytomegalovirus pneumonia with high-dose acyclovir
360. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant recipients receiving multiple courses of treatment with acyclovir
361. Neurological symptoms associated with parenteral acyclovir treatment after marrow transplantation
362. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation
363. Acyclovir resistance in a patient with chronic mucocutaneous herpes simplex infection
364. Plasma acyclovir concentrations in volunteers after multiple oral doses of acyclovir
365. Antiviral treatment of a serious herpes simplex infection: encephalitis
366. Vidarabine versus acyclovir therapy in herpes simplex encephalitis
367. Vidarabine versus acyclovir therapy of neonatal herpes simplex virus, HSV, infection
368. Pharmacokinetics of acyclovir in humans following intravenous administration
369. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy
370. Therapeutic challenge of neonatal herpes simplex virus infection
371. Design of therapeutic studies in herpes simplex encephalitis
372. Effectiveness of intravenous acyclovir in immunocompetent patient with herpes zoster encephalitis
373. Zur behandlung konnataler varizelien mit acyclovir
374. Efficacy of oral acyclovir treatment of acute herpes zoster. Antiviral Symposium
375. Effects of combined use of acyclovir and antibody in athymic nude mice inoculated intracutaneously with herpes simplex virus